Discussion on Merials canarypox-vectored equine influenza vaccine
Use the navigation bar above to access articles and more discussions on this topic.
| Author |
Message |
    
Robert N. Oglesby DVM
Moderator
Username: dro
Post Number: 17811
Registered: 1-1997
| | Posted on Monday, Feb 19, 2007 - 2:05 pm: |   |
We have been looking for published information on large efficacy studies with the new Merial influenza vaccine and here it is. The question of whether to use it is place of the intranasal MLV vaccine is not answered but it does look like a good product, particularly if the claim to preventing shedding of virus from vaccinated individuals holds up. Note the slightly altered vaccine schedule below compared with the label: a first booster at 5 months post primary series.
DrO
Am J Vet Res. 2007 Feb;68(2):213-9.
Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge.
Minke JM, Toulemonde CE, Coupier H, Guigal PM, Dinic S, Sindle T, Jessett D, Black L, Bublot M, Pardo MC, Audonnet JC.
Merial SAS, 254 rue Marcel Merieux, Lyon, 69007, France.
Objective-To determine onset and duration of immunity provided by a 2- or 3-dose series of a new canarypox-vectored recombinant vaccine for equine influenza virus (rCP-EIV vaccine) expressing the hemagglutinin genes of influenza H3N8 virus strains A/eq/Kentucky/94 and A/eq/Newmarket/2/93 in ponies. Animals-Forty-nine 1- to 3-year-old male Welsh Mountain Ponies that were seronegative for equine influenza virus. Procedures-Vaccinated and control ponies were challenged with aerosolized influenza virus A/eq/Sussex/89 (H3N8), representative of the Eurasian lineage of circulating influenza viruses. In trial 1, control ponies and ponies that received rCP-EIV vaccine were challenged 2 weeks after completion of the 2-dose primary vaccination program. In trial 2, ponies were challenged 5 months after 2 doses of rCP-EIV vaccine or 1 year after the first boosting dose of rCP-EIV vaccine, administered 5 months after completion of the primary vaccination program. After challenge, ponies were observed daily for clinical signs of influenza and nasal swab specimens were taken to monitor virus excretion. Results-The challenge reliably produced severe clinical signs consistent with influenza infection in the control ponies, and virus was shed for up to 7 days. The vaccination protocol provided clinical and virologic protection to vaccinates at 2 weeks and 5 months after completion of the primary vaccination program and at 12 months after the first booster. Conclusion and Clinical Relevance-The rCP-EIV vaccine provided protection of ponies to viral challenge. Of particular importance was the protection at 5 months after the second dose, indicating that this vaccine closes an immunity gap between the second and third vaccination. |
